Iron Deficiency, Anaemia in ChildrenPhase 3NCT05179226
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
A Phase 3 study testing Ferric Derisomaltose in people with Iron Deficiency, Anaemia in Children, run by Pharmacosmos A/S at 1 site in United States.
Trial summary
Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- Iron Deficiency, Anaemia in Children
- What is being tested?
- Ferric Derisomaltose
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Nov 2022to 30 Apr 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Subjects <18 years
- Informed consent and child assent, as age-appropriate, obtained before any trial- related activities and willingness to participate. LAR of the subject must sign and date the ICF (according to local requirements). The child must sign and date the CAF or provide oral assent, if required according to local requirements
- IDA caused by different etiologies such as gastrointestinal disease, NDD-CKD, or other conditions leading to IDA
- Hb concentration less than the 5th percentile for age and sex-specific reference range (Appendix B)
- Subjects with NDD-CKD (a) or who are intolerant or unresponsive to oral iron (b):
- Subjects with NDD-CKD:
Show all 12Show fewer
- TSAT ≤35 % or s-ferritin <100 ng/mL
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2
- If on ESA, receiving stable ESA regimen defined as dose adjustments no more than
- ± 20 % for ≥8 weeks prior to screening
- Subjects with documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to trial enrolment.
- TSAT ≤20 % or s-ferritin <100 ng/mL
Who cannot join
- Anemia caused by factors other than IDA according to Investigator's judgment
- S-ferritin >600 ng/mL
- Hb ≤5.0 g/dL
- Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
- ALAT and/or ASAT >2 times upper limit of normal (e.g. decompensated liver cirrhosis or active hepatitis)
- Pregnant or nursing female subjects. In order to avoid pregnancy, female subjects of childbearing potential have to use adequate contraception (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) or be abstinent during the whole trial period and 7 days after the last dosing. Childbearing potential refers to all female subjects ≥12 years old or <12 years old who have started menstruating
Show all 13Show fewer
- Previous serious hypersensitivity reactions to any IV iron compounds including ferric derisomaltose
- Received an investigational drug within 30 days prior to screening
- Treatment with IV iron within 10 days prior to screening
- Treatment with blood transfusion, radiotherapy, chemotherapy or other drugs that suppress the bone marrow, and drugs which have anemia as side effect within 30 days prior to screening
- Planned elective surgery (or planned surgery during the trial period) where significant blood loss is expected within the last 30 days prior to screening
- Any non-viral infection (non-viral infection that has been fully treated before the baseline visit is accepted)
- Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Pharmacosmos Investigational Site
Miami, Florida, 33142
About this study
Official title: A Phase III, Prospective, Open-label, Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Due to NDD-CKD or With Iron Deficiency Anemia Who Are Intolerant or Unresponsive to Oral Iron
Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. In fact, children are likely to develop IDA due to their rapid growth.
The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric derisomaltose in children 0 to <18 years of age with IDA due to NDD-CKD or with IDA who are intolerant or unresponsive to oral iron .
Read more
The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®/Monofer®), at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.
24 subjects will be part of a PK assessment, meaning that more blood samples will be drawn within the first week after treatment. The blood samples will be used for analysis of the amount of total iron in the blood from treatment is given to day 7.
For the individual subject, duration of the trial will be approximately 10 weeks (including a 14-day screening period) and each subject will attend 6-9 visits. Subjects who will be included in the PK assessments will attend 8 (subjects age 6 to <12 years old and 0 to <6 years old) or 9 (subjects age 12 to <18 years old) visits, while the other subjects will attend 6 visits.
Read the detailed description
This is a combined clinical pharmacology and phase III study. The study is a prospective, open-label, multi-center study. Children 0 to <18 years of age with iron deficiency anemia (IDA) with a) non-dialysis dependent chronic kidney disease (NDD-CKD) or b) who are intolerant or unresponsive to oral iron will be enrolled. The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®) at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.
A total of 200 subjects will be enrolled. Of these will 24 be part of the PK assessment. PK-subjects will be included in cohorts of 4 with the oldest age group as the first and with ferric derisomaltose 10 mg/kg to be increased to 20 mg/kg for the next cohort. Thus 12 subjects will be treated with 10mg/kg and the remaining 188 subjects with 20mg/kg.
- Conditions
- Iron Deficiency, Anaemia in Children
- Being tested
- Ferric Derisomaltose
- Medical subject headings
- Iron Deficiencies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ferric DerisomaltoseDrug
Also called Monofer®, Monoferric®
All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
| Study group | Role | What they receive |
|---|---|---|
| Ferric Derisomaltose | Experimental | All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg.
. Receives: Drug: Ferric Derisomaltose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.
Hb (g/dL), measurement by bloodsample analysis
Measured: From baseline at any time from week 1 to week 8
Secondary outcomes (13)
Time to increase Hb ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.
Hb (g/dL), measurement by bloodsample analysis
Measured: From baseline at any time from week 1 to week 8
Incidence of subjects who achieve a serum (s-) ferritin of ≥100 ng/mL. Measurement by bloodsample.
s-ferritin (ng/mL), measurement by bloodsample analysis
Measured: At weeks 1, 2, 4, and 8
Incidence of subjects who achieve a TSAT of ≥35 % (NDD-CKD) or ≥20 % (intolerant or unresponsive to oral iron). Measurement by bloodsample.
TSAT (%), measurement by bloodsample analysis
Measured: At weeks 1, 2, 4, and 8
Total iron PK parameters: AUC0-∞
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: AUC0-t
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: Cmax
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: Tmax
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: Ke
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: T½
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: CL
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Total iron PK parameters: Vd
Total iron (µg/dL), measurement by bloodsample analysis
Measured: From baseline to day 7
Type and incidence of AEs
Any AE
Measured: From baseline to week 8
Serious or severe hypersensitivity reaction
Any serious or severe hypersensitivity reaction
Measured: From treatment (Baseline) to 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2022
- Study start28 Nov 2022
- Primary completion30 Apr 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Iron Deficiency, Anaemia in ChildrenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The study includes a PK-part. 24 subjects will be part of a PK assessment and have total- iron PK-parameters measured 7 or 8 times between baseline visit and week 1.
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pharmacosmos A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05179226
- Sponsor's protocol ID
- P-Monofer-PED-01
- Other IDs
- U1111-1266-9073
- Status last verified
- Aug 2026
- First submitted
- 16 Nov 2021
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Prospective, Open-label, Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Due to NDD-CKD or With Iron Deficiency Anemia Who Are Intolerant or Unresponsive to Oral Iron
- ClinicalTrials.gov ID
- NCT05179226
- Acronym / sponsor ID
- P-Monofer-PED-01
- Conditions
- Iron Deficiency, Anaemia in Children
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Pharmacosmos A/SIndustry (pharma, biotech, devices)
- Study start
- 28 Nov 2022 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 5 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. In fact, children are likely to develop IDA due to their rapid growth.
The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric derisomaltose in children 0 to <18 years of age with IDA due to NDD-CKD or with IDA who are intolerant or unresponsive to oral iron .
The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®/Monofer®), at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.
24 subjects will be part of a PK assessment, meaning that more blood samples will be drawn within the first week after treatment. The blood samples will be used for analysis of the amount of total iron in the blood from treatment is given to day 7.
For the individual subject, duration of the trial will be approximately 10 weeks (including a 14-day screening period) and each subject will attend 6-9 visits. Subjects who will be included in the PK assessments will attend 8 (subjects age 6 to <12 years old and 0 to <6 years old) or 9 (subjects age 12 to <18 years old) visits, while the other subjects will attend 6 visits.
Detailed description
This is a combined clinical pharmacology and phase III study. The study is a prospective, open-label, multi-center study. Children 0 to <18 years of age with iron deficiency anemia (IDA) with a) non-dialysis dependent chronic kidney disease (NDD-CKD) or b) who are intolerant or unresponsive to oral iron will be enrolled. The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®) at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.
A total of 200 subjects will be enrolled. Of these will 24 be part of the PK assessment. PK-subjects will be included in cohorts of 4 with the oldest age group as the first and with ferric derisomaltose 10 mg/kg to be increased to 20 mg/kg for the next cohort. Thus 12 subjects will be treated with 10mg/kg and the remaining 188 subjects with 20mg/kg.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The study includes a PK-part. 24 subjects will be part of a PK assessment and have total- iron PK-parameters measured 7 or 8 times between baseline visit and week 1.
| Arm | Type | Receives |
|---|---|---|
| Ferric Derisomaltose | Experimental | Drug: Ferric DerisomaltoseAll subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg. . |
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (12 listed)
- Subjects <18 years
- Informed consent and child assent, as age-appropriate, obtained before any trial- related activities and willingness to participate. LAR of the subject must sign and date the ICF (according to local requirements). The child must sign and date the CAF or provide oral assent, if required according to local requirements
- IDA caused by different etiologies such as gastrointestinal disease, NDD-CKD, or other conditions leading to IDA
- Hb concentration less than the 5th percentile for age and sex-specific reference range (Appendix B)
- Subjects with NDD-CKD (a) or who are intolerant or unresponsive to oral iron (b):
Key exclusion criteria (13 listed)
- Anemia caused by factors other than IDA according to Investigator's judgment
- S-ferritin >600 ng/mL
- Hb ≤5.0 g/dL
- Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
- ALAT and/or ASAT >2 times upper limit of normal (e.g. decompensated liver cirrhosis or active hepatitis)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ferric DerisomaltoseAlso: Monofer®, Monoferric®All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg | Drug | Ferric Derisomaltose |
Primary outcome
Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.
Time frame: From baseline at any time from week 1 to week 8
Hb (g/dL), measurement by bloodsample analysis
13 secondary outcomes
Time to increase Hb ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.
Time frame: From baseline at any time from week 1 to week 8
Incidence of subjects who achieve a serum (s-) ferritin of ≥100 ng/mL. Measurement by bloodsample.
Time frame: At weeks 1, 2, 4, and 8
Incidence of subjects who achieve a TSAT of ≥35 % (NDD-CKD) or ≥20 % (intolerant or unresponsive to oral iron). Measurement by bloodsample.
Time frame: At weeks 1, 2, 4, and 8
Total iron PK parameters: AUC0-∞
Time frame: From baseline to day 7
Total iron PK parameters: AUC0-t
Time frame: From baseline to day 7
Total iron PK parameters: Cmax
Time frame: From baseline to day 7
Total iron PK parameters: Tmax
Time frame: From baseline to day 7
Total iron PK parameters: Ke
Time frame: From baseline to day 7
Total iron PK parameters: T½
Time frame: From baseline to day 7
Total iron PK parameters: CL
Time frame: From baseline to day 7
Total iron PK parameters: Vd
Time frame: From baseline to day 7
Type and incidence of AEs
Time frame: From baseline to week 8
Serious or severe hypersensitivity reaction
Time frame: From treatment (Baseline) to 24 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Iron Deficiency, Anaemia in Children
Not yet recruiting
Effect of Vitamin D Supplementation Added to Iron Therapy in Children With Iron Deficiency Anemia
Iron Deficiency Anemia
RecruitingObservational study
Maternal Iron Deficiency and Childhood Health
Iron Deficiency Anaemia in Childbirth, Iron Deficiency
Not yet recruitingPhase 2
COMPARISON OF EFFICACY OF ORAL VS IV IRON THERAPY IN CHILDREN AGED 12-59 MONTHS, WITH IRON DEFICIENCY ANEMIA
Iron Deficiency Anemia in Children
Recruiting
Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia
Celiac Disease in Children, Anemia
Not yet recruitingPhase 4
Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia
Iron Deficiency Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ferric Derisomaltose in people with Iron Deficiency, Anaemia in Children, run by Pharmacosmos A/S at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pharmacosmos A/S Clinical and Non-clinical Research (+4559485959, info@pharmacosmos.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample. (time frame: From baseline at any time from week 1 to week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.